The **bio-tech company AbbVie**, has enjoyed significant growth recently. It reported strong financial results for the full year and fourth quarter of 2024, with its stock rising 8% since Q4 earnings, causing it to be a topic of interest among investors. In addition, AbbVie's stocks have been lifted by Wilmington Savings Fund Society FSB, and several investment groups have boosted their stock holdings in AbbVie. An FDA approval was granted to a treatment for **intra-abdominal infections** jointly developed by **AbbVie and Pfizer**. Moreover, the company continues to make strategic advancements with the acquisition of Nimble Therapeutics and announcing updates on the ABBV-RGX-314 Clinical Program. Their 2025 profit forecasts, driven by their newer immunity drugs, were above estimates, contributing to increasing investor interest. Additionally, their Q4 earnings and revenues surpassed estimates, thanks to new drug sales. An interesting development was the FDA approval of **EMBLAVEO**, an antibiotic treatment by AbbVie. Due to these developments, the company has received a rating increase by various financial institutions.
Abbvie ABBV News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Sat, 08 Feb 2025 13:20:22 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -2
